Related Experiment Video
Updated: Aug 12, 2025
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
AI-Powered Biomolecular-Specific and Label-Free Multispectral Imaging Rapidly Detects Malignant Neoplasm in
Rishikesh Pandey1, David Fournier1, Gary Root1
1From the Department of Research, CytoVeris Inc, Farmington, Connecticut (Pandey, Fournier, Root, Riccio, Shirvalkar, Zamora, Daigneault, Sapack).
Context.—:
Repeated surgery is necessary for 20% to 40% of breast conservation surgeries owing to the unavailability of any adjunctive, accurate, and objective tool in the surgeon's hand for real-time margin assessment to achieve the desired balance of oncologic and cosmetic outcomes.
Objective.—:
To assess the feasibility of using a multispectral autofluorescence imaging device for discriminating malignant neoplasm from normal breast tissue in pathology as a critical step in the development of a device for intraoperative use, and to demonstrate the device's utility for use in processing and prioritizing specimens during frozen section and in the pathology grossing room.
Design.—:
We performed a preliminary assessment of our device, called the TumorMAP system, on 172 fresh tissue blocks from 115 patients obtained from lumpectomy specimens at the time of initial gross examination and compared the device results with gold standard pathology evaluation.
Results.—:
The preliminary results demonstrate the potential of our device in detecting breast cancer in fresh tissue samples with a sensitivity of 82%, a specificity of 91%, a positive predictive value of 84%, and a negative predictive value of 89%.
Conclusions.—:
Our results suggest that the TumorMAP system is suitable for the detection of malignant neoplasm in freshly excised breast specimens and has the potential to evaluate resection margins in real time.
Insights
A new multispectral autofluorescence imaging device, TumorMAP, shows promise for real-time breast cancer margin assessment. This technology could reduce repeat surgeries by accurately identifying malignant tissue during operations.
Area of Science:
- Oncology
- Medical Imaging
- Pathology
Background:
- Up to 40% of breast conservation surgeries require reoperation due to the lack of real-time margin assessment tools.
- Achieving optimal oncologic and cosmetic outcomes necessitates accurate intraoperative margin evaluation.
Purpose of the Study:
- To evaluate a multispectral autofluorescence imaging device (TumorMAP) for distinguishing malignant breast tumors from normal tissue.
- To assess the device's potential for intraoperative margin assessment and pathology specimen processing.
Main Methods:
- A preliminary study was conducted on 172 fresh lumpectomy tissue blocks from 115 patients.
- The TumorMAP system's performance was compared against standard pathology evaluation.
Main Results:
- The TumorMAP system demonstrated high accuracy in detecting breast cancer in fresh tissue.
- Sensitivity was 82%, specificity 91%, positive predictive value 84%, and negative predictive value 89%.
Conclusions:
- The TumorMAP system shows suitability for detecting malignant neoplasm in fresh breast specimens.
- The device holds potential for real-time evaluation of resection margins during surgery.
More Related Videos
11:27Quantitative Multispectral Analysis Following Fluorescent Tissue Transplant for Visualization of Cell Origins, Types, and Interactions
Published on: September 22, 2013
11:05Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery
Published on: September 19, 2014